Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Mediaven Forte - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Mediaven Forte

Approved

STANDARD

Mediaven Forte

Haupt Pharma Berlin GmbH🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 67b4487c0a64ed11
Company: Haupt Pharma Berlin GmbH
Type: Standard

Approval Details

Approval Id: 67b4487c0a64ed11
Drug Approval Philippines Name: Mediaven Forte
Product Name: Mediaven Forte
Registration Number: DR-XY41262
Brand Name: Mediaven Forte
Generic Name: Naftazone
Dosage Form: Film-Coated Tablet
Dosage Strength: 30 mg
Manufacturer: Haupt Pharma Berlin GmbH
Trader: Drossapharm AG
Importer: Multicare Pharmaceuticals Phils., Inc.
Distributor: Multicare Pharmaceuticals Phils., Inc.
Trader Detail Path: /organization/drossapharm-ag
Issuance Date: 27 May 2022
Expiry Date: 01 October 2025
Pharmacologic Category: Vasoprotective (Capillary Stabilizing Agent)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

67b4487c0a64ed11

Type

Standard

Back to Philippines FDA Approvals